腫瘤相關(guān)巨噬細胞（TAMs）是存在于腫瘤微環(huán)境中的一類免疫細胞，具有雙重作用：既可抑制腫瘤生長，也可促進腫瘤進展。它們主要來源于外周血單核細胞，受腫瘤分泌的趨化因子招募，并通過不同表型（如促炎的M1型和抑炎的M2型）影響腫瘤發(fā)展。目前，靶向TAMs已成為癌癥治療的研究熱點。促炎的M1型和抑炎的M2型巨噬細胞極化的兩種典型狀態(tài)的檢測，可以訂購靶點科技Cell-Out® M1巨噬細胞標(biāo)記和示蹤熒光探針，Cell-Out® M2巨噬細胞標(biāo)記和示蹤熒光探針。

使用荷蘭Liposoma巨噬細胞清除劑clodronateliposomes氯膦酸鹽脂質(zhì)體來清除腫瘤巨噬細胞，是在動物模型中研究巨噬細胞功能的重要手段之一。對于細胞接種動物腫瘤模型，一般持續(xù)要1周到4周不等。根據(jù)腫瘤細胞類型，小鼠背景，小鼠基因遺傳操作，腫瘤細胞修飾和改造，接種方式，關(guān)注階段等具體實驗的設(shè)計。巨噬細胞清除劑的給藥方案都不盡相同。如下這篇Nature Communications文獻，可以參考。

The evaluation of clodronate treatment on tumor progression of CI-competent and deficient tumors. (a) Tumor growth curves [n=6, df=10, t(day 35)=5.59] of HCT+/+ xenografts in ICRF nude mice treated with or without clodronate. Representative tumors are shown. Scale bar: 1 cm. (b) Haematoxylin/Eosin (HE) staining of HCT+/+ xenografts in ICRF nude mice treated with or without clodronate. Scale bars: 50 µm. Data are mean±s.e.m. (c) Tumor growth curves [data were log transformed, n=6, df=10, t(day33)=3.3] and excised tumor volume (n=6, df=10, t=2.5) of 143B-/- xenografts in Rag1-/-FVB mice treated with or without clodronate. Data are mean±s.e.m. Representative tumors are shown. Scale bar: 2 cm. (d) Representative images of immunofluorescent staining analyzing vessel morphology in 143B-/- xenografts treated with or without clodronate (n=4, df=6, t=3.16).

論文信息：

論文題目：Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses

期刊名稱：Nature Communications

時間期卷：10, Article number: 903(2019)

在線時間：2020年2月22日

DOI： doi.org/10.1038/s41467-019-08839-1

產(chǎn)品信息：

貨號：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes& Control Liposomes

辦事處：Target Technology(靶點科技)

Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體清除腫瘤相關(guān)巨噬細胞的材料和方法：

Depletion of macrophages

For the clodronate treatment experiments in Fig. 7c and Supplementary Fig. 17a–d, the animals were pre-injected intraperitoneally with PBS or clodronate liposomes (100?µL, ClodronateLiposomes, Liposoma BV) on the day prior to cell injection. On the day of tumor cell injection, 5?×?106 cells in growth factor reduced matrigel (100?µL) were injected subcutaneously, immediately followed by injection of 40?µL of PBS or clodronate liposomes at the same position. The mice continued to receive intraperitoneal injection of liposomes twice weekly (100?µL).

材料和方法文獻截圖：